Vaccine Safety Articles & Analysis
20 news found
Utilizing system biology approaches, adjuvant, mRNA, and vector-based technologies, Protheragen provides mRNA vaccine, DNA vaccine, live-attenuated vaccine, virus-like particle vaccine, protein subunit vaccine, and many other custom vaccines. Protheragen’s vaccine ...
By prioritizing optimization, Alfa Chemistry ensures that their mRNA vaccine solutions remain at the forefront of the industry, consistently delivering vaccines that redefine the boundaries of vaccine technology. mRNA Vaccine Quality Control Equally crucial to the success of mRNA vaccine solutions is an ...
Challenges in viral vaccine manufacturing: “The product is the process” In the vaccine field, “the product is the process”. ...
ByNuvonis
CD BioGlyco, a biotechnology company specialized in the field of glycobiology, has developed a series of advanced vaccine development platforms by integrating various advanced technologies to promote the development of glycol-based vaccines. ...
ANGANY’s primary focus is the development of therapeutic vaccines, leveraging the unique immunogenicity and safety profile of its plant-based eBioparticle™ technology. The initial two product candidates for human medicine are vaccines against cat allergy and peanut allergy, the first of which will enter clinical development in the ...
At the completion of year two, the safety of the vaccine was assessed by an independent Data Safety Monitoring Board (DSMB), chaired by Dr. Rod Page at Colorado State University. The DSMB did not identify any vaccine associated serious adverse events. The safety will be monitored yearly, and at the end of years ...
ByCalviri
The primary endpoints of these trials include safety and feasibility. Secondary endpoints include biological activity of the therapeutic vaccine TG4050. ...
BlueWillow Biologics, Inc. today announced that the company will present positive interim data from its phase 1 clinical trial of a novel intranasal anthrax vaccine at a Lightning Talks Session of BARDA’s Industry Day, November 3 and 4, 2021. BlueWillow’s rPA/NE01 anthrax vaccine, BW-1010, developed in collaboration with Porton Biopharma Limited (UK) ...
The Vaccine Against Canine Cancer Study (VACCS) trial (www.vaccs.org) reported its formal two-year evaluation of the safety of a vaccine to prevent cancer in healthy dogs. ...
ByCalviri
But on a more immediate basis, the company has worked hard to ensure the safety of its employees and its customers through the use of mandated health and safety procedures applied to the manufacturing and shipping of its entire product line. ...
– Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Micron’s Microneedle-Based Measles-Rubella Vaccine – ATLANTA, July 13, 2021 /PRNewswire/ – Micron Biomedical, Inc. (“Micron” or the “Company”), a leader in dissolving, microneedle-based vaccine and drug delivery, today ...
Thanks to this decision, the National Vaccination Program is launched. Our company, as one of the largest manufacturers of pharmaceutical refrigerators and ultra-low freezers, is also actively involved in this program. One of the requirements for vaccination points under this program is to have a refrigerator for vaccines with temperature ...
With the recent approval of a COVID-19 vaccine, there is great hope that there will soon be an end to what is arguably the most painful and deadliest public health crisis in our country’s history. ...
HBsAg VLPs are a licensed vaccine with excellent safety and immunogenicity data in humans and which are currently manufactured to billions of doses. ...
These initial clinical data support the further development of MV-012-968 for RSV and the application of Meissa’s technology to a COVID-19 vaccine candidate. Meissa’s COVID-19 vaccine candidate, MV-014-210, was developed on the company’s codon deoptimized RSV vaccine platform with the goal of creating safe, potent, stable, ...
The main objectives were to evaluate the safety and the immunogenicity after 3 subcutaneous injections with the CV-MG01 vaccine Population of subjects: The therapeutic vaccine (or placebo) was tested on 24 patients with Myasthenia Gravis, a chronic autoimmune neuromuscular disorder (mean age: 42 years, 24 – 64 years; 18 females, 6 males) ...
Imaxio, a biotech company specialized in immunology, announces today that the results of its tuberculosis vaccine phase I clinical trial have been published in the journal Vaccine. The trial, which was conducted by the Jenner Institute at Oxford University (UK), has proved that the vaccine candidate (and thus IMX313, Imaxio’s antigen ...
MosquirixTM aims at addressing the objectives set for a first generation vaccine in the WHO malaria vaccine technology roadmap. The roadmap also outlines ambitious goals for second generation vaccines including transmissionblocking vaccines. ...
"One issue is that, although computers are ubiquitous across Africa, high-speed Internet is not," said Hakeem Oluseyi, interim president of the society. More>> HIV vaccine trial starts in South Africa Research to establish whether a vaccine can stem progression of disease in people already infected with HIV has started at the University of Limpopo. ...
Parents across the world have come forth blaming their childrens' autism on the MMR vaccination, which contains thimerosal, a form of mercury. Though it is controversial whether there is any connection, the reality is that the symptoms of autism are nearly identical to those of mercury poisoning (Bernard et al, 2000). ...